CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. - Wikidata - awgldk - TriplyDB

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

http://www.wikidata.org/entity/Q34707604

about

Influence of immunoglobulin isotype on therapeutic antibody function Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Lymphoma Immunotherapy: Current Status Immune Modulation in Hematologic Malignancies Enhancing Cancer Immunotherapy Via Activation of Innate Immunity Natural killer cell biology: an update and future directions Modulation of GITR for cancer immunotherapy 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses 4-1BB agonism: adding the accelerator to cancer immunotherapy Mechanisms of action of therapeutic antibodies for cancer Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients NK cell-based immunotherapy for malignant diseases.Targeting CD137 enhances the efficacy of cetuximab.Targeting secondary immune responses to cetuximab: CD137 and the outside story.Combination immunotherapy: a road map.Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.Agonist antibodies to TNFR molecules that costimulate T and NK cells NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.Haematological malignancies: at the forefront of immunotherapeutic innovation.Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptors Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.Cancer immunotherapy: Strategies for personalization and combinatorial approaches.Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.Combination immune therapies to enhance anti-tumor responses by NK cells.

P2860

Q26772080-90311F87-DA66-4EF2-9E0D-7D398317AE8A Q26772347-84C1D6D5-FEF3-46BA-A3DE-369A917A06FB Q26774678-3F513C01-C5E2-4AEF-8B6F-33FDED065673 Q26782902-829DA72C-33B0-45FC-A60E-5C6146DC6FDD Q26796307-F3C66CE1-C6D5-436E-B47B-D9FD3BF1EC97 Q26796313-1083492C-E65E-432E-8792-E6434F7E9831 Q26830512-7F1AB793-486E-4CF2-B3F1-17B9FD19F78C Q26853557-EA8A7249-B111-40E5-848A-07CBD3D94F30 Q27012963-91BAC8F8-7CDB-46D9-931F-C065C616C9E2 Q27694769-C786CA7F-3DC0-492D-9148-63746AC66A1F Q28072933-DD8DC4B2-74C7-445C-8BF2-AA682D785F2D Q28079622-8B928F29-AFE1-4A57-8924-15131D870A6B Q28385366-A3D663A5-D657-42B0-A0D3-55FA12C7928C Q30356145-1137992B-1AA5-4907-BF70-B09116125469 Q30456436-18063C6C-4F8B-4639-822E-B3DE60471C48 Q33434322-1C613AD0-9EA8-4280-8AEC-B1B0C25FEA00 Q33809528-76F9E90C-E6F0-46AB-BCE5-F2A0F880937F Q33827433-C5B0E51F-9514-4636-8EFF-FF2A7111A648 Q33872482-0827EAC2-19FC-4208-B8B0-0E8938F61F66 Q33872496-273A1380-748C-4185-B8C2-0E08DC5E0E79 Q34552128-1C1880F4-5775-415B-9C2D-B8C59C80A8D5 Q34598149-34B0B0AE-0CA3-4BAC-B174-20F8C13CF30A Q34978570-C4F35335-3F89-463E-B3BE-3EFD661BEED1 Q35031732-F56727F9-8713-4CB1-AE36-D7AB9E04363E Q35153794-D533B1D3-F24E-4490-B4BE-395337134933 Q35427446-BD78B61A-8EA5-4A79-8A12-78944B089C84 Q35506745-46BF9AF8-873E-430C-955D-F0A209C50D9D Q35764479-56CCC76B-7FB5-4146-9305-08E4ABDE4859 Q35780315-BF4A90C8-C49B-431C-8B94-ABFD66966E0A Q35880618-79050A73-0694-4859-A74C-3CCD6E34F59A Q35922726-7438E15D-0337-4790-ACFD-BF963D89EA22 Q36102906-1878D154-E861-4650-85BB-35E4012A5498 Q36190723-73542170-6E71-476A-9042-F6DD410CCC2D Q36220613-8D85C1F5-3B04-4129-A2FB-F10688F87DA9 Q36387028-C45C9CC3-03DC-45FE-863F-A7A70CA6C6FC Q36597479-F94647BD-E1BF-47CB-BCB6-3D12FAB07F9C Q36752738-137E41E1-81DC-46DC-8AA7-F99EA97F7169 Q37012676-464CD2AA-AFCC-4504-AEA4-4DA4453D1537 Q37222143-6D131944-0065-4CB0-B9EC-98E4E6C7DA51 Q37408550-2098D5F4-C1AC-439E-9B99-B76CD4636D0D

P2860

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

http://www.wikidata.org/entity/Q34707604

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

@ast

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

@en

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

@nl

type

label

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

@ast

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

@en

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

@nl

prefLabel

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

@ast

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

@en

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

@nl

P1433

Q34707604-005C7AD1-12ED-4ABF-865C-63BCA9CEA75D

P1476

Q34707604-25D5A8DB-68D3-4372-B850-CD4F850A238B

P2093

Q34707604-0BE63ED4-511A-4105-8EBB-AB2B82A3E620

Q34707604-18DF5446-6FC2-4ABA-9CA2-538AC86C3ABF

Q34707604-1A3F08E6-C0B5-4B6D-9BA6-5FDA4AB07465

Q34707604-407C8E75-51A4-4702-AE2B-AD3B7EF6FD26

Q34707604-67D3539A-9407-444B-B7E1-9F8D578E0D20

Q34707604-6C0DE9B4-8B03-4173-874E-226B25EB5A1B

Q34707604-6DEA0EAD-D1D4-414E-9C02-257387F5BC31

Q34707604-88CAE295-A100-4D99-A229-5280DAED2E5C

Q34707604-8AEDAEC5-9AA8-4465-A0D8-EBE1B3E2DDED

Q34707604-90220266-76A1-47FD-87ED-CA349E9C0A48

P2860

Q34707604-16E1B883-FF48-41C7-A32C-0035006B2E22

Q34707604-1760B088-20A9-42E2-AAE3-1B567D8511FB

Q34707604-1FF8DBE9-65AF-4856-BF15-200548A2F0C5

Q34707604-2F6F87A4-8CF5-4557-AFBF-D2B3BB0AFBF6

Q34707604-44C1969D-0EBA-47B5-9363-72184F8BCBF1

Q34707604-46432BF1-B278-4231-B75E-D7CE92B743A6

Q34707604-4CBB4D58-1BDC-4B20-B84D-06A857E73ACE

Q34707604-546F100E-7C4C-4DBE-9DAB-CFD203BB5AEC

Q34707604-60D40900-92EE-4D2C-B788-3359F8C0D9D4

Q34707604-653880A0-70A9-407F-AF27-1753F3550633

P304

Q34707604-ABC4A358-1356-4D36-BC47-AD6010E8D4D8

P31

Q34707604-FE4C40A7-BF01-42F1-9E18-4A0F8863DE24

P356

Q34707604-A2B6148D-CFFB-4B77-9C89-D6D14B0367D7

P407

Q34707604-A609BAA8-3041-44A9-8536-739565D5F327

P433

Q34707604-FB6B38BC-18D8-4C92-AC67-54276DDF9DB9

P478

Q34707604-120D5570-5B52-4C77-8D5C-73456D63A97A

P577

Q34707604-CAF775AA-0C49-446B-9789-9980D0A1B53D

P5875

Q34707604-E2878F03-0E48-4F14-9E46-64A441558E86

P698

Q34707604-8AF82DBD-3D62-498D-B47C-8F1B3F87C724

P921

Q34707604-E2A0AC4A-A4E1-4810-B0BD-5D1C0364B32B

P932

Q34707604-5506FC74-64CA-4870-8F14-02EDA847E5AB

P356

BLOOD-2010-08-301945

P1433

P1476

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

@en

P2093

Antonia Müller

http://www.w3.org/2001/XMLSchema#string

Ash A Alizadeh

http://www.w3.org/2001/XMLSchema#string

Debra Czerwinski

http://www.w3.org/2001/XMLSchema#string

Holbrook E Kohrt

http://www.w3.org/2001/XMLSchema#string

Josh Brody

http://www.w3.org/2001/XMLSchema#string

Kipp Weiskopf

http://www.w3.org/2001/XMLSchema#string

Lieping Chen

http://www.w3.org/2001/XMLSchema#string

Mark P Chao

http://www.w3.org/2001/XMLSchema#string

Matthew J Goldstein

http://www.w3.org/2001/XMLSchema#string

Roch Houot

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Cutting edge: Expression of functional CD137 receptor by dendritic cells

TNF/TNFR family members in costimulation of T cell responses

Cancer statistics, 2009

CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.

4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

The biology of human natural killer-cell subsets.

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

P304

2423-2432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-08-301945

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49716854

http://www.w3.org/2001/XMLSchema#string

P698

21193697

http://www.w3.org/2001/XMLSchema#string

P921

P932

3062409

http://www.w3.org/2001/XMLSchema#string